作　　者： ; ; ; ; ;

机构地区： 安徽省立医院

出　　处： 《现代肿瘤医学》 2016年第14期2265-2268,共4页

摘　　要： 目的:本文通过病例报道及文献复习,探讨哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)抑制剂治疗转移性肾癌(metastatic renal cell carcinoma,mRCC)的药理作用及临床研究进展。方法:回顾1例mRCC的临床资料,分析替西罗莫司治疗的疗效及不良反应,同时复习近5年关于mRCC及mTOR抑制剂的143篇文献,深入了解mTOR抑制剂治疗mRCC的药理作用,总结临床应用现状。结果:患者无进展生存期(progression-free-survival,PFS)为7.5个月,主要不良反应为血红蛋白减少,胆固醇及甘油三酯均有升高。结论:患者经替西罗莫司治疗,不良反应少,耐受性较好,并取得了较好的客观疗效。因此,mTOR抑制剂治疗在mRCC治疗中有一定的优势,值得临床进一步研究。 Objective:We retrospectively analyzed the clinical data of 1 case of metastatic renal cell carcinoma (mRCC)patient with sorafenib failure, and reviewed related literature. To explore the pharmacological mechanisms and advancement of mammalian target of rapamycin ( mTOR) inhibitors in mRCC therapy. Methods : To review the clinical data of 1 case of mRCC,and analyze the therapy curative effect and adverse reaction of temsirolimus. Mean-while, to review the recent five year articles about mRCC and mTOR inhibitors in order to make a deep understanding of the pharmacological effects of mTOR inhibitors in mRCC therapy. Results:The patient had progression - free - sur-vival PFS) of 7. 5. The most common side effects included anemia,hyperglycemia and hypertriglyceridemia. Conclu-sion : Temsirolimus had better clinical effects.

关 键 词： 肾细胞癌 靶向治疗 替西罗莫司